D Gensburger1,2, S Boutroy3, R Chapurlat3,4, R Nove-Josserand5, S Roche6, M Rabilloud6, I Durieu5. 1. INSERM UMR 1033, Université de Lyon, Lyon, France. deborah.gensburger@chu-lyon.fr. 2. Department of Rheumatology, Hôpital E. Herriot, Hospices Civils de Lyon, Lyon, France. deborah.gensburger@chu-lyon.fr. 3. INSERM UMR 1033, Université de Lyon, Lyon, France. 4. Department of Rheumatology, Hôpital E. Herriot, Hospices Civils de Lyon, Lyon, France. 5. Cystic Fibrosis Adult Reference Centre, Department of Internal Medicine, Université de Lyon, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France. 6. Department of Biostatistique, Hospices Civils de Lyon; Université de Lyon. Université Lyon 1, CNRS UMR558, Laboratoire de Biométrie et Biologie évolutive, Equipe Biostatistique-Santé, Villeurbanne, France.
Abstract
UNLABELLED: In our current adult CF population, low BMD prevalence was only 20 %, lower than that historically described. We found a mild increase of serum RANK-L levels, independent from the bone resorption level. The increased fracture risk in CF may be explained by a lower tibial cortical thickness and total vBMD. INTRODUCTION: Bone disease is now well described in cystic fibrosis (CF) adult patients. CF bone disease is multifactorial but many studies suggested the crucial role of inflammation. The objectives of this study were, in a current adult CF population, to assess the prevalence of bone disease, to examine its relationship with infections and inflammation, and to characterize the bone microarchitecture using high resolution peripheral scanner (HR-pQCT). METHODS: Fifty-six patients (52 % men, 26 ± 7 years) were assessed in clinically stable period, during a respiratory infection, and finally 14 days after the end of antibiotic therapy. At each time points, we performed a clinical evaluation, lung function tests, and biochemical tests. Absorptiometry and dorso-lumbar radiographs were also performed. A subgroup of 40 CF patients (63 % men, 29 ± 6 years) underwent bone microarchitecture assessment and was age- and gender-matched with 80 healthy controls. RESULTS: Among the 56 CF patients, the prevalence of low areal BMD (T-score < -2 at any site), was 20 % (95 % CI: [10.2 %; 32.4 %]). After infections, serum RANK-L (+24 %, p = 0.08) and OPG (+13 %, p = 0.04) were increased with a stable ratio. Microarchitectural differences were mostly observed at the distal tibia, with lower total and cortical vBMD and trabecular thickness (respectively -9.9, -3.0, and -5 %, p < 0.05) in CF patients compared to controls, after adjustment for age, gender, weight, and height. CONCLUSIONS: In this study, bone disease among adult CF patients was less severe than that previously described with only 20 % of CF patients with low BMD. We found a mild increase of biological marker levels and an impaired volumetric density of the tibia that may explain the increased fracture risk in CF population.
UNLABELLED: In our current adult CF population, low BMD prevalence was only 20 %, lower than that historically described. We found a mild increase of serum RANK-L levels, independent from the bone resorption level. The increased fracture risk in CF may be explained by a lower tibial cortical thickness and total vBMD. INTRODUCTION:Bone disease is now well described in cystic fibrosis (CF) adult patients. CF bone disease is multifactorial but many studies suggested the crucial role of inflammation. The objectives of this study were, in a current adult CF population, to assess the prevalence of bone disease, to examine its relationship with infections and inflammation, and to characterize the bone microarchitecture using high resolution peripheral scanner (HR-pQCT). METHODS: Fifty-six patients (52 % men, 26 ± 7 years) were assessed in clinically stable period, during a respiratory infection, and finally 14 days after the end of antibiotic therapy. At each time points, we performed a clinical evaluation, lung function tests, and biochemical tests. Absorptiometry and dorso-lumbar radiographs were also performed. A subgroup of 40 CFpatients (63 % men, 29 ± 6 years) underwent bone microarchitecture assessment and was age- and gender-matched with 80 healthy controls. RESULTS: Among the 56 CFpatients, the prevalence of low areal BMD (T-score < -2 at any site), was 20 % (95 % CI: [10.2 %; 32.4 %]). After infections, serum RANK-L (+24 %, p = 0.08) and OPG (+13 %, p = 0.04) were increased with a stable ratio. Microarchitectural differences were mostly observed at the distal tibia, with lower total and cortical vBMD and trabecular thickness (respectively -9.9, -3.0, and -5 %, p < 0.05) in CFpatients compared to controls, after adjustment for age, gender, weight, and height. CONCLUSIONS: In this study, bone disease among adult CFpatients was less severe than that previously described with only 20 % of CFpatients with low BMD. We found a mild increase of biological marker levels and an impaired volumetric density of the tibia that may explain the increased fracture risk in CF population.
Entities:
Keywords:
Bone microarchitecture; Bone turnover; Cystic fibrosis; Fracture; Osteoporosis; RANK-L
Authors: Pawel Szulc; Stéphanie Boutroy; Nicolas Vilayphiou; Ali Chaitou; Pierre D Delmas; Roland Chapurlat Journal: J Bone Miner Res Date: 2011-06 Impact factor: 6.741
Authors: Melissa S Putman; Joshua F Baker; Ahmet Uluer; Karen Herlyn; Allen Lapey; Leonard Sicilian; Angela Pizzo Tillotson; Catherine M Gordon; Peter A Merkel; Joel S Finkelstein Journal: J Cyst Fibros Date: 2015-02-16 Impact factor: 5.482
Authors: Elizabeth F Shead; Charles S Haworth; Alison M Condliffe; Damian J McKeon; Mike A Scott; Juliet E Compston Journal: Thorax Date: 2007-07 Impact factor: 9.139
Authors: D E Whittier; S K Boyd; A J Burghardt; J Paccou; A Ghasem-Zadeh; R Chapurlat; K Engelke; M L Bouxsein Journal: Osteoporos Int Date: 2020-05-26 Impact factor: 4.507
Authors: Melissa S Putman; Logan B Greenblatt; Michael Bruce; Taisha Joseph; Hang Lee; Gregory Sawicki; Ahmet Uluer; Leonard Sicilian; Isabel Neuringer; Catherine M Gordon; Mary L Bouxsein; Joel S Finkelstein Journal: J Clin Endocrinol Metab Date: 2021-03-08 Impact factor: 5.958